Smell and Taste Loss Associated with COVID-19 Infection.
COVID-19
gustatory dysfunction
olfactory dysfunction
smell loss
taste loss
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
31
03
2023
received:
25
01
2023
accepted:
12
05
2023
medline:
11
8
2023
pubmed:
2
6
2023
entrez:
2
6
2023
Statut:
ppublish
Résumé
The aim of this study was to quantify the impact of COVID-19 on olfactory and gustatory function in US adults. From the 2021 Adult National Health Interview Survey, demographic and survey-specific module data concerning COVID-19 diagnoses, testing and disease severity, and data quantifying disturbances and eventual recovery of smell and taste were extracted. Sample weights were applied to obtain nationally representative statistics. The overall rate of COVID-19 infection was determined, and those diagnosed with COVID-19 were analyzed with respect to disease severity, smell and taste disturbance, and respective recoveries. In 2021, 35.8 million or 14% of the adult population (95% CI 13.5-14.7%; mean age, 43.9 years; 53.8% female) had been diagnosed with COVID-19. Among those, 60.5% (58.6-62.5%) and 58.2% (56.2-60.1%) reported accompanying losses in smell or taste, respectively; there was a significant association between overall COVID-19 symptom severity and smell (p < 0.001) and taste disturbance (p < 0.001). Following infection, 72.2% (69.9-74.3%), 24.1% (22.2-26.2%), and 3.7% (3.0-4.6%) of the patients experienced complete, partial, and no smell recovery, respectively. Recovery rates for gustatory function paralleled olfaction, with 76.8% (74.6-78.9%), 20.6% (18.7-22.7%), and 2.6 (1.9-3.4%) reporting complete, partial, and no recovery of taste, respectively. When sensory disturbance was present, severity of overall symptomatology was negatively associated with smell and taste recovery (p < 0.001 for each). The majority of adults infected with COVID-19 in 2021 experienced olfactory or gustatory dysfunction with a non-negligible population reporting incomplete or no near-term sensory recovery. Our results are useful for providers counseling patients and suggest that interventions lessening overall COVID-19 symptom burden may prevent prolonged sensory dysfunction. 4 Laryngoscope, 133:2357-2361, 2023.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2357-2361Informations de copyright
© 2023 The American Laryngological, Rhinological and Otological Society, Inc.
Références
World Health Organization. World Health Statistics 2023. World Health Organization; 2023. Accessed March 15, 2023. https://www.who.int/data/stories/world-health-statistics-2021-a-visual-summary.
Centers for Disease Control. Symptoms of COVID-19. Centers for Disease Control; 2022 Accessed October 6, 2022. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci. 2020;35(18):e174. https://doi.org/10.3346/jkms.2020.35.e174.
Lechien JR, Chiesa-Estomba CM, de Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-2261. https://doi.org/10.1007/s00405-020-05965-1.
Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H, SeyedAlinaghi S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. Eur Arch Otorhinolaryngol. 2021;278(2):307-312. https://doi.org/10.1007/s00405-020-06120-6.
Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinol J. 2020;58(3):299-301. https://doi.org/10.4193/Rhin20.114.
Khani E, Khiali S, Beheshtirouy S, Entezari-Maleki T. Potential pharmacologic treatments for COVID-19 smell and taste loss: a comprehensive review. Eur J Pharmacol. 2021;912:174582. https://doi.org/10.1016/j.ejphar.2021.174582.
Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020;163(1):3-11. https://doi.org/10.1177/0194599820926473.
Renaud M, Thibault C, le Normand F, et al. Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis. JAMA Netw Open. 2021;4(6):e2115352. https://doi.org/10.1001/jamanetworkopen.2021.15352.
Printza A, Katotomichelakis M, Metallidis S, et al. The clinical course of smell and taste loss in COVID-19 hospitalized patients. Hippokratia. 2020;24(2):66-71.
Amer MA, Elsherif HS, Abdel-Hamid AS, Elzayat S. Early recovery patterns of olfactory disorders in COVID-19 patients; a clinical cohort study. Am J Otolaryngol. 2020;41(6):102725. https://doi.org/10.1016/j.amjoto.2020.102725.
Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022;378:e069503. https://doi.org/10.1136/bmj-2021-069503.
Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(8):1621-1631. https://doi.org/10.1016/j.mayocp.2020.05.030.
IBM. SPSS. IBM Corp; 2022.
Bhattacharyya N, Kepnes LJ. Contemporary assessment of the prevalence of smell and taste problems in adults. Laryngoscope. 2015;125(5):1102-1106. https://doi.org/10.1002/lary.24999.
Institute for Health Metrics and Evaluation. COVID-19 Results Briefing. Institute for Health Metrics and Evaluation; 2022. Accessed October 7, 2022.
Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life-an updated review. Chem Senses. 2014;39(3):185-194. https://doi.org/10.1093/chemse/bjt072.
Coelho DH, Reiter ER, Budd SG, Shin Y, Kons ZA, Costanzo RM. Quality of life and safety impact of COVID-19 associated smell and taste disturbances. Am J Otolaryngol. 2021;42(4):103001. https://doi.org/10.1016/j.amjoto.2021.103001.
Jeon S, Kim Y, Min S, Song M, Son S, Lee S. Taste sensitivity of elderly people is associated with quality of life and inadequate dietary intake. Nutrients. 2021;13(5):1693. https://doi.org/10.3390/nu13051693.
Smeets MAM, Veldhuizen MG, Galle S, et al. Sense of smell disorder and health-related quality of life. Rehabil Psychol. 2009;54(4):404-412. https://doi.org/10.1037/a0017502.
Hummel T, Landis BN, Hüttenbrink KB. Smell and taste disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2011;10:Doc04. https://doi.org/10.3205/cto000077.
Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. https://doi.org/10.1038/s41368-020-0074-x.
Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021;184(24):5932-5949.e15. https://doi.org/10.1016/j.cell.2021.10.027.
Butowt R, Meunier N, Bryche B, von Bartheld CS. The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. Acta Neuropathol. 2021;141(6):809-822. https://doi.org/10.1007/s00401-021-02314-2.
Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect. 2022;28(4):612.e1-612.e7. https://doi.org/10.1016/j.cmi.2021.11.010.
Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407-1416. https://doi.org/10.1016/S0140-6736(21)02183-8.
Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high risk patients. Clin Infect Dis. 2023;76(3):e342-e349. https://doi.org/10.1093/cid/ciac443.
Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med. 2022;54(1):516-523. https://doi.org/10.1080/07853890.2022.2034936.
Mattos JL, Schlosser RJ, Storck KA, Soler ZM. Understanding the relationship between olfactory-specific quality of life, objective olfactory loss, and patient factors in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(7):734-740. https://doi.org/10.1002/alr.21940.
Desiato VM, Levy DA, Byun YJ, Nguyen SA, Soler ZM, Schlosser RJ. The prevalence of olfactory dysfunction in the general population: a systematic review and meta-analysis. Am J Rhinol Allergy. 2021;35(2):195-205. https://doi.org/10.1177/1945892420946254.
Menachemi N, Dixon BE, Wools-Kaloustian KK, et al. How many SARS-CoV-2-infected people require hospitalization? Using random sample testing to better inform preparedness efforts. J Public Health Manag Pract. 2021;27(3):246-250. https://doi.org/10.1097/PHH.0000000000001331 PMID: 33729203.